

TABLE I. Cytotoxicity of BS-1

	IC ₅₀ (μg/ml)
P388-D1 mouse leukemia	4
P388 mouse leukemia	3
P815 mouse mastocytoma	0.6
EL4 mouse lymphoma	0.8
BW5147 mouse lymphoma	13
J774-1 mouse leukemia	10
BALB/3T3 mouse embryo	>25
Vero monkey kidney	>25
MOLT4 human lymphoma	3
U937 human lymphoma	12
EJ-1 human bladder carcinoma	13
HLE human hepatoma	13
TYK-nu human ovary carcinoma	10
A549 human lung carcinoma	>25

-CH₂CH₂OH moiety in BS-1. Based on the combined evidence, BS-1 has been assigned as bis(2-hydroxyethyl) trisulfide.

Furthermore, BS-1 isolated from *B. stearothermophilus* was found to be identical with the synthetic compound^{2,8)} by direct comparison of their ¹H-NMR, EI-MS, thin layer chromatographic (TLC) and high performance liquid chromatographic (HPLC) data. Synthetic compound BS-1 inhibited the proliferation of P388-D1 at doses ranging from 0.5 to 10 μg/ml as well as the native one, and its 50% inhibitory concentration (IC₅₀) was 4 μg/ml. Further, BS-1 was effective against leukemia P388, mastocytoma P815, lymphoma EL4 and lymphoma MOLT4 at low concentrations. BS-1 has weak cytotoxic activity against lymphoma BW5147, leukemia J774-1 and several human tumor cell lines (Table I). On the other hand, BS-1 did not show antimicrobial activity against *Staphylococcus aureus* 209P, *Bacillus subtilis* ATCC 6633, *Escherichia coli* NIHJ JC-2, *Candida albicans* and *Asperigius fumigatus* (MIC were more than 10 μg/ml), and antiviral activity against HSV (MIC were more than 33 μg/ml).

BS-1 must be a secondary metabolite of the strain UK563, because it was isolated from both autolysate and culture filtrate. Although this compound has already been synthesized as a useful reagent in the manufacture of liquid polymer and in vulcanization technology,^{2,8)} this report presents the first instance of a natural occurrence and the biological aspect of the compound. Naturally occurring cyclic polysulfide compounds, 1,2,3-trithiane derivatives in tunicate,⁹⁾ ascidian,¹⁰⁾ asparagus¹¹⁾ and alga^{7b,12)} have been reported to exhibit *in vitro* antimicrobial, antileukemia and cytotoxic properties.¹⁰⁾ Recently, diallyl or alkenyl trisulfide compounds present in garlic and onion oil have been shown to inhibit chemical carcinogenesis.¹³⁾ The biological activity of these organosulfur compounds likely originates from unsaturated alkyl groups rather than polysulfide.¹³⁾ A novel class of potent antitumor antibiotics, esperamicins¹⁴⁾ and calicheamicins¹⁵⁾ containing bicyclo[7.3.1]diene and methyl trisulfide has been dis-

covered in bacteria. Interestingly, the enediyne system can be readily triggered to aromatize *via* a free radical intermediate by cleavage at the methyl trisulfide moiety. It has been reported that bis(2-hydroxyethyl) trisulfide in aqueous solution can be cleaved to produce (2-hydroxyethyl)perthiyl (RSS·) radicals and 2-hydroxyethanethiol by the reducing radicals; such as e_{aq}⁻ and ·CO₂⁻.^{8a)} The cytotoxicity of BS-1 may be due to the radical production, but it requires confirmation.

Since BS-1 consists chemically of a simple structure, it seems to be a degraded metabolite. Several peaks with cytotoxic activity, which were less active than that of BS-1, existed in HPLC on octadecyl silica (ODS). It is possible to consider that the activity originates from BS-1 analogues in strain UK563. Anyway, it is interesting to clarify the physiological significance of trisulfide compound in thermophile.

Acknowledgement We are grateful to the Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd. for measurements of antimicrobial activity and antiviral activity.

References and Notes

- 1) a) Part I: Y. Kohama, T. Nakagawa, H. Oka, Y. Okuno, T. Mimura, H. Tsujibou, Y. Inamori, R. Tsurutani, K. Nagata and K. Tomita, *Agric. Biol. Chem.*, **54**, 2115 (1990); b) Part II: Y. Kohama, T. Teramoto, K. Iida, N. Murayama, T. Semba, N. Tatebatake, Y. Kayamori, K. Tsujikawa and T. Mimura, *Chem. Pharm. Bull.*, **39**, 2468 (1991); c) Part III: Y. Kohama, N. Murayama, K. Tanaka, A. Inada, T. Nakanishi, M. Itoh, X. Ying and T. Mimura, *ibid.*, **39**, 3378 (1991).
- 2) D. N. Harpp, K. Stelion and T. H. Chan, *J. Am. Chem. Soc.*, **100**, 1222 (1978).
- 3) K. Saotome, H. Morita and M. Umeda, *Toxicol. in Vitro*, **3**, 317 (1989).
- 4) H. M. Shapiro, "Practical Flow Cytometry," 2nd ed., Wiley-Liss, New York, 1988, p. 129.
- 5) M. C. Alley, D. A. Scudiero, A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbot, J. G. Mayo, R. H. Shoemaker and M. R. Boyd, *Cancer Res.*, **48**, 4827 (1988).
- 6) F. C. Robbins, J. F. Enders and T. H. Weller, *Proc. Soc. Exp. Biol. Med.*, **75**, 370 (1950).
- 7) a) A. Kato, Y. Hashimoto, I. Otsuka and K. Nakatsu, *Chem. Lett.*, **1978**, 1219; b) U. Anthoni, C. Christophersen, J. Madsen, S. Wium-Andersen and N. Jacobsen, *Phytochemistry*, **19**, 1228 (1980).
- 8) a) Z. Wu, T. G. Back, R. Ahmad, R. Yamadagni and D. A. Armstrong, *J. Phys. Chem.*, **86**, 4417 (1982); b) A. Duda and S. Penczek, *Makromol. Chem. Rapid Commun.*, **9**, 151 (1988).
- 9) M. Litaudon and M. Guyot, *Tetrahedron Lett.*, **32**, 911 (1991).
- 10) B. R. Corpp, J. W. Blunt and M. H. G. Munro, *Tetrahedron Lett.*, **30**, 3703 (1989).
- 11) T. Kasai and S. Sakanuma, *Agric. Biol. Chem.*, **46**, 821 (1982).
- 12) S. J. Wratten and D. J. Faulkner, *J. Org. Chem.*, **41**, 2465 (1976).
- 13) V. L. Sparnins, G. Barany and L. W. Wattenberg, *Carcinogenesis*, **9**, 131 (1988); S. Belman, J. Solmon, A. Segal, E. Block and G. Barany, *J. Biochem. Toxicology*, **4**, 151 (1989); H. Sumiyoshi and M. J. Worgovich, *Cancer Res.*, **50**, 5084 (1990).
- 14) J. Golok, G. Dubay, G. Groenewold, H. Kawaguchi, M. Konishi, B. Krishnan, H. Ohkuma, K. Saitoh and T. W. Doyle, *J. Am. Chem. Soc.*, **109**, 3462 (1987).
- 15) M. D. Lee, T. S. Dunne, C. C. Chang, G. A. Ellestad, M. M. Siegel, G. O. Morton, W. J. McGahan and D. B. Borders, *J. Am. Chem. Soc.*, **109**, 3466 (1987).